Business Wire

Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador

Share

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213824479/en/

Five-time Olympic Medalist and fashion icon, Gabby Thomas, is the latest ambassador to join Amazfit's growing roster of elite athletes. (Graphic: Business Wire)

As the 200m, 4x100m and 4x400m gold medalist, Thomas left the 2024 Paris Olympics as the most decorated U.S. track and field athlete at the Games. Additionally, she holds multiple Diamond League titles and took home two additional Olympic medals - 200m (bronze) and 4x100m (silver) - at the 2020 Tokyo Games. The partnership with Amazfit is Thomas’ first with a smartwatch and gives credence to the benefits data can play on athletic performance.

“I’m really excited to partner with Amazfit because, for me, the little things make all the difference,” said Thomas. “As an athlete, this is the exact type of partnership that will help me continue to get better. It's so important to have objective data on my body—whether it’s tracking my heart rate during a workout, seeing how well I’ve recovered, or understanding how much quality sleep I’m getting. Having a reliable smart wearable brand like Amazfit in my corner is a game-changer."

As part of this exciting partnership, Thomas will enhance her training by incorporating Amazfit's smart wearables analysis into her preparation and recovery to improve performance and help break future records. She will also provide insights and feedback to Amazfit’s development and design teams on product future features and styles.

"We are honored to have Gabby join the Amazfit team," said Wayne Huang, Founder & CEO, Zepp Health. "Her remarkable athletic career and passion for style align closely with our mission to unlock the limits of human potential to ‘Discover Amazing.’ Through this partnership, we will continue to empower athletes to unleash their full potential by rewriting the record books utilizing our advanced smart wearables ecosystem."

Amazfit is committed to creating products that empower holistic health and well-being, and that healthy living requires balance across four key pillars of wellness: physical fitness, sleep, mindfulness and nutrition. Amazfit’s diverse product portfolio includes Active, Cheetah and T-Rex series performance smartwatches, Helio smart ring and the Zepp App, all designed to help athletes and health enthusiasts track and enhance their holistic health. The Zepp App’s latest Food Log feature offers athletes like Thomas an unparalleled ability to bridge the gap between nutrition and fitness, ensuring peak performance and optimal recovery. Whether monitoring heart rate, tracking sleep cycles, or logging meals, Amazfit provides the insights needed to maintain a well-rounded approach to health.

Thomas joins a growing list of Amazfit athletes, including HYROX World Champions Meg Jacoby and Hunter McIntyre, Padel star Bea González and Olympians Morgan Pearson (triathlon) and Yemaneberhan "Yeman" Crippa (5k & 10k).

Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at www.amazfit.com.

For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.

Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213824479/en/

Contacts

MEDIA CONTACT
Mary Thompson Woodbury
mary.woodbury@zepp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 14:05:00 EEST | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transform not only the country but the EU,” said Niccolo de Masi, Chairman and CEO of IonQ. “Through this landmark quantum collabora

Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 13:01:00 EEST | Press release

Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective cooling. The outcome is less pipe clutter, and less noise for mo

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will be presented, highlighting promising antitumor activity and a generally manageable safety and tolerability profile in patients with advanced solid tumors. “The results presented at ESMO 2025 strengthen the evidence base for TEVIMBRA in lung cancer, with consistent survival ben

SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 12:00:00 EEST | Press release

SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock

New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EUR neffy ® , Now Available in the UK20.10.2025 11:01:00 EEST | Press release

For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye